



ASX and Media Release

CAVATAK activity in lung cancer presented at international oncolytic virus conference

14 April 2014, Sydney, Australia: Viralytics Limited (ASX:VLA, OTC:VRACY) is pleased to announce that results from a pre-clinical research project focussing on the positive activity of CAVATAK™ in lung cancer have been presented at The Eighth International Conference on Oncolytic Virus Therapeutics in Oxford, UK on 10-13 April 2014.

The presentation is entitled:

Synergistic Activity of Coxsackievirus A21 (CVA21) and Docetaxel in Non-Small Cell Lung Cancer (NSCLC)

The poster, presented by Viralytics' research team members Yvonne Vern Yee Wong and Min Yuan Quah, reports on the synergistic activity between CAVATAK™ and the commonly used chemotherapeutic agent Docetaxel in pre-clinical models of lung cancer.

In vitro studies showed synergy between CAVATAK™ and Docetaxel in multiple lung cancer cell lines. In mouse xenograft models the best response was observed in mice receiving the combination of CAVATAK™ and the commonly administered chemotherapeutic agent Docetaxel. Importantly, Docetaxel was not detrimental to the effectiveness of CAVATAK™ when the two agents were used in combination.

Viralytics Chief Executive Officer, Dr Malcolm McColl said: "The findings from this new study are further evidence that the oncolytic immunotherapy activity of CAVATAK™, when administered with Docetaxel, may be a promising treatment strategy for lung cancer. This result provides further encouragement for our investigation of CAVATAK™ in the recently initiated STORM study including patients with lung cancer. Success in this setting would significantly broaden the commercial application and benefit many more cancer patients."

The poster presentation is available on the Viralytics website.

Enquiries:

Dr Malcolm McColl
Chief Executive Officer
02 9988 4000

Mr Rudi Michelson
Monsoon Communications
03 9620 3333

About Viralytics Ltd:

Viralytics is developing oncolytic immunotherapy treatments for a range of cancers. Viralytics' lead investigational product, CAVATAK™, is a proprietary formulation of the common cold Coxsackievirus Type A21 (CVA21). CVA21 binds to specific 'receptor' proteins highly expressed on multiple cancer types including, but not limited to: melanoma; prostate, lung, breast and bladder cancers; and multiple myeloma. CAVATAK™ acts to kill both local and metastatic cancer cells through cell lysis and the potential generation of an immune response

For personal use only



against the cancer cells. Together this mechanism of action is known as oncolytic immunotherapy. CAVATAK™'s preferential targeting of cancer cells provides the potential for low toxicity in the patient.

The company has fully enrolled a phase 2 clinical trial of intratumourally administered CAVATAK™ in the treatment of Late stage Melanoma (the CALM study), at multiple prestigious cancer clinics in the US.

Viralytics has commenced a Phase 1/2 trial of CAVATAK™ delivered systemically (intravenously). This trial, referred to as the STORM (Systemic Treatment Of Resistant Malignancies) study, is enrolling patients with melanoma, prostate, lung or metastatic bladder cancers. The second stage of the STORM trial will include combination treatments with existing chemotherapies in one of the above cancer types. The STORM trial is being conducted at three UK cancer centres.

Based in Sydney Australia, the company is listed on the Australian Securities Exchange (ASX: VLA) while Viralytics' ADRs also trade under VRACY on the US OTCQX International market.

For personal use only